JPH06511244A - バナジウム組成物 - Google Patents
バナジウム組成物Info
- Publication number
- JPH06511244A JPH06511244A JP5506591A JP50659193A JPH06511244A JP H06511244 A JPH06511244 A JP H06511244A JP 5506591 A JP5506591 A JP 5506591A JP 50659193 A JP50659193 A JP 50659193A JP H06511244 A JPH06511244 A JP H06511244A
- Authority
- JP
- Japan
- Prior art keywords
- vanadium
- compound
- human
- group
- complex compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (22)
- 1.バナジウムをキレート化して、バナジウム含有不飽和5員環(この環は少な くとも2個の異種原子を更に含有する)を形成しうる2座配位単変キレート化剤 の、生理的に許容されるバナジウム錯化合物を、生理的に許容される少なくとも 1種の担体と一緒に含有することを特徴とする、製剤組成物。
- 2.一般式I ▲数式、化学式、表等があります▼(I)(式中、X1およびX2は独立して、 酸素、硫黄またはNX6であり;X2は窒素またはCX7であり; X4、X5、X6、およびX7は独立して、安定なプロトン、または所望により 置換されたアルキル基、アリール基、アラルキル基またはアルカリール基であり 、あるいはX4〜X7の少なくとも1対は、介在する原子と一緒になって、所望 により置換された飽和または不飽和の炭素環または複素環を示し、あるいはX1 がNX6であるときは、X4はX8Hを示してもよく、ここでX6は酸素または 硫黄であり;X1またはX8と結合しているプロトンの一つは化学的に不安定で ある) で表される2座配位単変キレート化剤の、生理的に許容されるバナジウム錯化合 物を、生理的に許容される少なくとも1種の担体と一緒に含有することを特徴と する、製剤組成物。
- 3.上記のキレート化剤が、ヒドロキサメート、α−ヒドロキシカルボニル化合 物、およびシステイン以外のα−アミノ酸から選ばれたものである、請求の範囲 第1項または第2項に記載の組成物。
- 4.上記のキレート化剤が、α−ヒドロキシピロンまたはα−ヒドロキシピリジ ノンである、請求の範囲第3項に記載の組成物。
- 5.上記のキレート化剤が、マルトールまたはコウシ酸である、請求の範囲第4 項に記載の組成物。
- 6.上記の錯化合物が、バナジウム(IV)または(V)錯化合物である、請求 の範囲第1項〜第5項のいずれかに記載の組成物。
- 7.上記の錯化合物が、オキソバナジウム(IV)錯化合物である、請求の範囲 第1項〜第5項のいずれかに記載の組成物。
- 8.生理的に許容されるバナジウム化合物を、少なくとも1種の担体または賦形 剤と一緒に含有することを特徴とする、肥満または高血圧の処置に用いられる製 剤組成物。
- 9.上記のバナジウム化合物が、有機バナジウム塩またはバナジウム錯化合物で ある、請求の範囲第8項に記載の組成物。
- 10.上記のバナジウム化合物が、請求の範囲第1項〜第7項のいずれかで定義 された錯化合物である、請求の範囲第9項に記載の組成物。
- 11.注射による非経口投与に適する形態にある、請求の範囲第1項〜第10項 のいずれかに記載の組成物。
- 12.経口投与に適する形態にある、請求の範囲第1項〜第9項のいずれかに記 載の組成物。
- 13.皮下投与、腹腔内投与または経皮投与に適する形態にある、請求の範囲第 1項〜第10項のいずれかに記載の組成物。
- 14.治療に使用するための、ビス(コウシャート)オキソバナジウム(IV) 。
- 15.治療に使用するための、ビス(マルトラート)オキソバナジウム(IV) 。
- 16.請求の範囲第1項〜第7項のいずれかで定義されたバナジウム錯化合物の 、血糖レベルを低下させるための治療剤の製造への使用。
- 17.請求の範囲第1項〜第15項のいずれかで定義されたバナジウム化合物の 、抗高圧剤として用いるための薬剤の製造への使用。
- 18.請求の範囲第1項〜第15項のいずれかで定義されたバナジウム化合物の 、食欲抑制剤として用いるための薬剤の製造への使用。
- 19.ヒトまたはヒト以外の哺乳動物の身体に、請求の範囲第1項〜第6項のい ずれかで定義されたバナジウム錯化合物を投与することを特徴とする、ヒトまた はヒト以外の哺乳動物の身体を、血糖レベルを低下させるように処置する方法。
- 20.ヒトまたはヒト以外の哺乳動物の身体に、請求の範囲第1項〜第15項の いずれかで定義されたバナジウム化合物を投与することを特徴とする、ヒトまた はヒト以外の哺乳動物の身体を、高められた血圧を低下させるように処置する方 法。
- 21.ヒトまたはヒト以外の哺乳動物の身体に、請求の範囲集1項〜第15項の いずれかで定義されたバナジウム化合物を投与することを特徴とする、ヒトまた はヒト以外の哺乳動物の身体を、食欲を抑制するように処置する方法。
- 22.投与を経口的に行うことを特徴とする、請求の範囲第19項〜第21項の いずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/767,510 US5300496A (en) | 1991-09-30 | 1991-09-30 | Complexed vanadium for the treatment of diabetes mellitus |
US767,510 | 1991-09-30 | ||
PCT/EP1992/002235 WO1993006811A2 (en) | 1991-09-30 | 1992-09-29 | Vanadium compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06511244A true JPH06511244A (ja) | 1994-12-15 |
JP3515107B2 JP3515107B2 (ja) | 2004-04-05 |
Family
ID=25079727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50659193A Expired - Fee Related JP3515107B2 (ja) | 1991-09-30 | 1992-09-29 | バナジウム組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5300496A (ja) |
EP (2) | EP0811380A3 (ja) |
JP (1) | JP3515107B2 (ja) |
AT (1) | ATE162716T1 (ja) |
AU (1) | AU2649792A (ja) |
CA (1) | CA2120338A1 (ja) |
DE (1) | DE69224293T2 (ja) |
DK (1) | DK0606318T3 (ja) |
ES (1) | ES2112329T3 (ja) |
GR (1) | GR3026654T3 (ja) |
NZ (1) | NZ244569A (ja) |
WO (1) | WO1993006811A2 (ja) |
ZA (1) | ZA927522B (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527790A (en) * | 1991-09-30 | 1996-06-18 | The University Of British Columbia | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar |
US5866563A (en) * | 1991-09-30 | 1999-02-02 | The University Of British Columbia | Vanadium compositions |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
US5871779A (en) * | 1994-01-18 | 1999-02-16 | Mount Sinai Hospital Corporation | Treatment of arthropathies with vanadate compounds or analogues thereof |
US5565491A (en) * | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
GB9416767D0 (en) * | 1994-08-18 | 1994-10-12 | Nycomed Innovation Ab | Compositions |
US5863519A (en) * | 1994-08-18 | 1999-01-26 | Nycomed Imaging As | Composition and method of MRI using both a positive and a negative contrast agent |
WO1996005867A2 (en) * | 1994-08-18 | 1996-02-29 | Nycomed Imaging A/S | Compositions |
GB9416768D0 (en) * | 1994-08-18 | 1994-10-12 | Nycomed Innovation Ab | Compositions |
US5547685A (en) * | 1995-05-16 | 1996-08-20 | Eli Lilly And Company | Methods for inhibiting bone loss with vanadyl sulfate |
US5545661A (en) * | 1995-05-16 | 1996-08-13 | Eli Lilly And Company | Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds |
US5885980A (en) * | 1996-06-25 | 1999-03-23 | Enrique G. Gutierrez | Composition and method for treating diabetes |
US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
US6232340B1 (en) | 1997-04-24 | 2001-05-15 | Angiotech Pharmaceuticals, Inc. | Vanadium complexes and derivatives thereof and methods related thereto |
EP0984971A1 (en) * | 1997-04-24 | 2000-03-15 | Angiotech Pharmaceuticals, Inc. | Vanadium complexes and derivatives thereof and methods related thereto |
US6245808B1 (en) * | 1998-11-05 | 2001-06-12 | Parker Hughes Institute | Oxy-vanadium (IV) complexes having spermicidal activity |
US6432941B1 (en) | 1998-01-20 | 2002-08-13 | Parker Hughes Institute | Vanadium compounds for treating cancer |
US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
WO2000015211A2 (en) | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders |
US6287586B1 (en) | 1998-09-18 | 2001-09-11 | The University Of British Columbia | Pharmaceutical compositions of vanadium biguanide complexes and their use |
WO2000024730A1 (en) | 1998-10-28 | 2000-05-04 | The University Of British Columbia | Organic vanadium(iii) complexes and their use |
GB2396106B (en) * | 2002-12-12 | 2006-11-15 | Johnson & Johnson Medical Ltd | Wound dressings comprising enzyme inhibitors |
AU2005259231A1 (en) * | 2004-07-02 | 2006-01-12 | Genmedica Therapeutics Sl | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of diabetes mellitus |
US20060165814A1 (en) * | 2004-12-16 | 2006-07-27 | Genmedica Therapeutics Sl | Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
US20070066682A1 (en) * | 2005-07-01 | 2007-03-22 | Exposito Miriam R | Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus |
US20080070987A1 (en) * | 2006-05-12 | 2008-03-20 | Francesc Yraola Font | Meta-xylylenediamine vanadate salts |
AU2012226703A1 (en) | 2011-03-07 | 2013-10-17 | Cfm Pharma Holding Bv | Use of vanadium compounds for maintaining normaglycemia in a mammal |
WO2012131689A1 (en) | 2011-03-25 | 2012-10-04 | Chaudhuri Mihir K | Insulin mimetic active comprising oxodiperoxo vanadates and a pharamaceutical composition obtained thereof |
JP7349052B2 (ja) * | 2019-06-24 | 2023-09-22 | 湖南方升泰医薬科技有限公司 | 金属錯体の新規応用 |
CN111035652B (zh) * | 2020-01-08 | 2021-08-24 | 辽宁大学 | 钒酸盐酪蛋白复合物在制备降糖药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1277599C (en) * | 1986-10-16 | 1990-12-11 | Barry I. Posner | Vanadium - peroxide compositions as insulin mimickers |
FR2619382B1 (fr) * | 1987-08-11 | 1990-05-04 | Lazaro Rene | Compose organo-mineral de vanadyle, procede d'obtention d'un tel compose, composition pharmaceutique contenant ce compose organo-mineral |
JPH02292217A (ja) * | 1989-05-08 | 1990-12-03 | Otsuka Pharmaceut Co Ltd | 糖尿病治療薬 |
-
1991
- 1991-09-30 US US07/767,510 patent/US5300496A/en not_active Expired - Lifetime
-
1992
- 1992-09-29 JP JP50659193A patent/JP3515107B2/ja not_active Expired - Fee Related
- 1992-09-29 CA CA002120338A patent/CA2120338A1/en not_active Abandoned
- 1992-09-29 ES ES92920526T patent/ES2112329T3/es not_active Expired - Lifetime
- 1992-09-29 DK DK92920526T patent/DK0606318T3/da active
- 1992-09-29 AT AT92920526T patent/ATE162716T1/de not_active IP Right Cessation
- 1992-09-29 DE DE69224293T patent/DE69224293T2/de not_active Expired - Fee Related
- 1992-09-29 AU AU26497/92A patent/AU2649792A/en not_active Abandoned
- 1992-09-29 EP EP97200558A patent/EP0811380A3/en not_active Withdrawn
- 1992-09-29 WO PCT/EP1992/002235 patent/WO1993006811A2/en active IP Right Grant
- 1992-09-29 EP EP92920526A patent/EP0606318B1/en not_active Expired - Lifetime
- 1992-09-30 ZA ZA927522A patent/ZA927522B/xx unknown
- 1992-09-30 NZ NZ244569A patent/NZ244569A/en unknown
-
1998
- 1998-04-15 GR GR980400857T patent/GR3026654T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2649792A (en) | 1993-05-03 |
CA2120338A1 (en) | 1993-04-15 |
DE69224293D1 (de) | 1998-03-05 |
EP0606318A1 (en) | 1994-07-20 |
GR3026654T3 (en) | 1998-07-31 |
EP0811380A2 (en) | 1997-12-10 |
EP0811380A3 (en) | 1999-01-20 |
WO1993006811A2 (en) | 1993-04-15 |
ZA927522B (en) | 1993-06-16 |
DK0606318T3 (da) | 1998-09-23 |
US5300496A (en) | 1994-04-05 |
ES2112329T3 (es) | 1998-04-01 |
NZ244569A (en) | 1995-04-27 |
JP3515107B2 (ja) | 2004-04-05 |
EP0606318B1 (en) | 1998-01-28 |
ATE162716T1 (de) | 1998-02-15 |
WO1993006811A3 (en) | 1993-06-24 |
DE69224293T2 (de) | 1998-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06511244A (ja) | バナジウム組成物 | |
US5620967A (en) | Methods of treating hypertension with vanadium compositions | |
Thompson et al. | Vanadium compounds in the treatment of diabetes | |
US5866563A (en) | Vanadium compositions | |
Nahas | The clinical pharmacology of THAM [tris (hydroxymethyUami nomethane] | |
Bellet et al. | Effect of vomiting due to intestinal obstruction on the serum potassium: Chemical and electrocardiographic observations in fifteen cases preliminary report | |
US5077313A (en) | Process for inhibiting pathological collagen cross-linking in diabetes patients | |
Atkinson | The use of N-acetylcysteine in intensive care | |
JPH06501000A (ja) | グルタミンを用いるグルタチオンレベルの増大法 | |
US5422125A (en) | Method and composition for treatment of insulin resistance syndromes | |
JP4306825B2 (ja) | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 | |
Motil et al. | Complications of essential amino acid hyperalimentation in children with acute renal failure | |
Nappi et al. | Severe hypoglycemia associated with disopyramide. | |
FI68970C (fi) | Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening | |
US7008937B2 (en) | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | |
Villalba-Pimentel et al. | Survival after massive procainamide ingestion | |
JPH07506568A (ja) | 糖尿病治療のための既存の薬剤の使用 | |
SE457958B (sv) | Vattenloeslig hemin-arginat eller hemin-lysinat-foerening, foerfarande foer framstaellning daerav samt anvaendning daerav foer tillverkning av medicinska kompositioner | |
RU2559894C1 (ru) | Комплексное соединение оксованадия (iv) с диметилсульфоксидом, обладающее антидиабетическим действием, и способ его получения | |
Okada et al. | Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy | |
WO2001003700A1 (en) | Combination of chromium and vanadium for glucose metabolism disorders | |
JP2889374B2 (ja) | ソマトスタチン活性ポリペプチドを活性成分とする医薬組成物 | |
RU2136288C1 (ru) | Способ лечения сахарного диабета | |
JPS5914006B2 (ja) | グルコ−ス含有注入溶液 | |
Coulston et al. | Comparison of parenterally administered calcium kinate gluconate with calcium gluconate and calcium chloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040115 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090123 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100123 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100123 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100123 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100123 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |